SAN DIEGO, CA April 3, 2007/MarketWire/– Aegis Therapeutics, a leader in intranasal drug delivery, will present a talk entitled: “High-Efficiency Delivery of Peptides, Proteins, and Other Macromolecules via Intranasal & Other Transmucosal Routes” at the Arrowhead “Drug Delivery 2007 Conference”. The conference will be held on April 10, 2007 at the Crown Plaza Union Square, San Francisco. Dr. Edward T. Maggio, President and CEO of Aegis, will describe the application of Aegis’ Intravail® non-invasive drug delivery technology, and Aegis’ ProTek® protein stabilization technology to specific peptide and protein therapeutics.
Information about the conference may be obtained from the following website: http://www.arrowheadpublishers.com/conferences/drugdelivery2007/.
About Aegis Therapeutics
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Our Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics that can currently only be administered by injection. Aegis’ Intravail® absorption enhancement agents provide exceptionally high and unmatched bioavailability performance, comparable in efficiency to subcutaneous injection, via the intranasal and other mucosal membrane administration routes. Our ProTek® technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek® technology is applicable to injectable, intranasal, and other dosage forms of peptide or protein therapeutics.
For more information about Aegis, please visit the Aegis website at: htpp://www.aegisthera.com.